Premium
Circulating placental proteins (hCG, SP 1 and PP5) in trophoblastic disease
Author(s) -
LEE J. N.,
SALEM H. T.,
CHARD T.,
HUANG S. C.,
OUYANG P. C.
Publication year - 1982
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1982.tb04639.x
Subject(s) - choriocarcinoma , mole , radioimmunoassay , trophoblast , gestational trophoblastic disease , glycoprotein , chorioepithelioma , endocrinology , medicine , biology , andrology , placenta , pregnancy , gestation , microbiology and biotechnology , fetus , genetics
Summary. Scrum human chorionic gonadotrophin (hCG), pregnancyspecific β 1 ‐glycoprotein (SP 1 ) and placental protein 5 (PP5) levels have been measured by radioimmunoassay in 20 patients (116 samples) with hydatidiform mole, one patient (nine samples) with invasive mole and 10 patients (103 samples) with choriocarcinoma. Measurement of both serum SP 1 and hCG are useful in the monitoring of these diseases. The presence of PP5 in hydatidiform mole and its absence in choriocarcinoma support the hypothesis that PP5 is closely associated with the invasive activity of malignant trophoblast.